Cargando…
Update on new biologics for intractable eosinophilic asthma: impact of reslizumab
A small percentage of patients with asthma have uncontrolled symptoms and frequent exacerbations, despite treatment with inhaled corticosteroids and other agents. It has become clear that different subtypes of this severe, treatment-resistant group exist due to different mechanisms of the disease. A...
Autores principales: | Sahota, Jagdeep, Robinson, Douglas S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951215/ https://www.ncbi.nlm.nih.gov/pubmed/29780238 http://dx.doi.org/10.2147/DDDT.S109489 |
Ejemplares similares
-
Role of biologics in severe eosinophilic asthma – focus on reslizumab
por: Pelaia, Girolamo, et al.
Publicado: (2016) -
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
por: Walsh, Garry M
Publicado: (2013) -
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
por: Varricchi, Gilda, et al.
Publicado: (2017) -
Successful treatment of refractory eosinophilic fasciitis with reslizumab
por: Mortezavi, Mahta, et al.
Publicado: (2020) -
Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
por: Pérez de Llano, Luis A, et al.
Publicado: (2022)